Cancer drug effective fertility treatment

US researchers randomly assigned 750 infertile women aged 18—40 diagnosed using the Rotterdam criteria to receive up to five cycles of either clomiphene or letrozole, an aromatase inhibitor for the treatment of hormone-dependent breast cancer in postmenopausal women.

Dosage was increased in subsequent cycles to a maximum daily dose of clomiphene of 150mg and a maximum daily dose of 7.5mg of letrozole for five days.

More than a quarter of women (27.5%) receiving letrozole went on to have a live birth compared 9.1% of those receiving clomiphene.

There were no significant differences in congenital anomalies between the groups but there were four major congenital abnormalities in the letrozole group compared to one in the clomiphene group.

The cumulative ovulation rate was higher with letrozole, and